The aim of the study was to assess the efficacy of lamotrigine (LTG) in 15 outpatients, mean age 47.33±3.24 SE, affected by bipolar disorders, including the subtype 'rapid cycling', in partial remission (DSM IV). Side effects and hematological toxicity of LTG were also evaluated. The patients were treated with an initial mean dose of 41.66 mg/die±5.27 SE, then, from the first month (T2) with a mean dose of 130 mg/die±25.76 SE. Clinical assessment was performed by BPRS, HRS-A, HRS-D and MRS at time 0 (T0), 15 (T1), 30 days (T2), then every month for 13 months (T14). The rating scales evaluation evinced a stability of clinical picture. The major side effects were cephalalgy (6%) and rush (2%), both independent by the dosage of LTG. The periodic control of hemochrome did not emphasize hematological toxicity relative to all period of the study. Further controlled studies on a large patient population are desirable.
|Translated title of the contribution||Lamotrigine. An alternative drug in the prophylaxis of bipolar disorders|
|Number of pages||5|
|Publication status||Published - 1998|
ASJC Scopus subject areas
- Psychiatry and Mental health